Hakan Kardes Sells 14,500 Shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Hakan Kardes sold 14,500 shares of the stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $14.98, for a total value of $217,210.00. Following the transaction, the insider now owns 295,444 shares in the company, valued at approximately $4,425,751.12. This trade represents a 4.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Hakan Kardes also recently made the following trade(s):

• On Tuesday, January 21st, Hakan Kardes sold 10,500 shares of Alignment Healthcare stock. The shares were sold at an average price of $14.99, for a total transaction of $157,395.00.
• On Wednesday, November 27th, Hakan Kardes sold 35,000 shares of Alignment Healthcare stock. The stock was sold at an average price of $12.80, for a total value of $448,000.00.
• On Monday, November 4th, Hakan Kardes sold 20,500 shares of Alignment Healthcare stock. The shares were sold at an average price of $13.06, for a total transaction of $267,730.00.
• On Friday, November 1st, Hakan Kardes sold 4,500 shares of Alignment Healthcare stock. The shares were sold at an average price of $12.98, for a total transaction of $58,410.00.

Alignment Healthcare Trading Up 2.7 %

ALHC traded up $0.40 during mid-day trading on Friday, reaching $14.97. The stock had a trading volume of 2,062,404 shares, compared to its average volume of 1,865,740. The firm’s fifty day simple moving average is $12.13 and its two-hundred day simple moving average is $10.99. The stock has a market capitalization of $2.87 billion, a P/E ratio of -19.44 and a beta of 1.45. Alignment Healthcare, Inc. has a 52 week low of $4.46 and a 52 week high of $15.05. The company has a debt-to-equity ratio of 1.82, a quick ratio of 1.60 and a current ratio of 1.60.

Alignment Healthcare (NASDAQ:ALHC) last released its earnings results on Tuesday, October 29th. The company reported ($0.14) EPS for the quarter, hitting analysts’ consensus estimates of ($0.14). Alignment Healthcare had a negative net margin of 5.84% and a negative return on equity of 108.69%. The firm had revenue of $692.43 million during the quarter, compared to analyst estimates of $662.11 million. During the same quarter in the previous year, the business earned ($0.19) EPS. The business’s quarterly revenue was up 51.6% compared to the same quarter last year. On average, equities analysts predict that Alignment Healthcare, Inc. will post -0.69 EPS for the current year.

Hedge Funds Weigh In On Alignment Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the company. R Squared Ltd acquired a new stake in shares of Alignment Healthcare in the 4th quarter valued at about $55,000. SG Americas Securities LLC boosted its stake in shares of Alignment Healthcare by 11.7% during the 4th quarter. SG Americas Securities LLC now owns 49,272 shares of the company’s stock worth $554,000 after buying an additional 5,163 shares during the last quarter. Ballentine Partners LLC acquired a new stake in shares of Alignment Healthcare in the fourth quarter valued at about $121,000. JPMorgan Chase & Co. boosted its position in Alignment Healthcare by 249.3% during the third quarter. JPMorgan Chase & Co. now owns 288,219 shares of the company’s stock valued at $3,407,000 after purchasing an additional 205,705 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Alignment Healthcare by 1,335.1% during the 3rd quarter. Principal Financial Group Inc. now owns 194,043 shares of the company’s stock worth $2,294,000 after purchasing an additional 180,522 shares in the last quarter. 86.19% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on ALHC. Barclays upped their price target on Alignment Healthcare from $7.00 to $8.00 and gave the company an “underweight” rating in a report on Wednesday, October 30th. Stephens reissued an “overweight” rating and issued a $17.00 price target on shares of Alignment Healthcare in a report on Thursday, January 2nd. UBS Group lifted their target price on shares of Alignment Healthcare from $9.00 to $12.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Stifel Nicolaus raised their price target on shares of Alignment Healthcare from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, January 14th. Finally, KeyCorp began coverage on Alignment Healthcare in a research note on Friday, October 11th. They issued a “sector weight” rating on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Alignment Healthcare currently has an average rating of “Moderate Buy” and a consensus price target of $11.88.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.